Amplia widens the narmafotinib net with ovarian cancer study

Amplia Therapeutics has given investors a fresh reason to look beyond pancreatic cancer, signing an agreement with the Australia New Zealand Gynaecological Oncology Group to run a new ovarian cancer study of its lead drug narmafotinib.

The planned PRROSE trial will test narmafotinib alongside standard chemotherapy, carboplatin and paclitaxel, in about 15-20 patients with high-grade serous ovarian cancer who have responded poorly to initial platinum-based chemotherapy ahead of planned interval debulking surgery. That is a small study, but for an ASX biotech with a market value around $72 million, it is potentially useful clinical optionality without requiring a swing-for-the-fences phase three cheque just yet.

Why ovarian cancer, and why now?

The logic is biological as much as commercial. Amplia says ovarian cancer is a major target for FAK inhibition because these tumours often show higher FAK expression and a fibrous tumour environment. FAK, or focal adhesion kinase, is involved in the way cancer cells interact with their surroundings, and narmafotinib is designed to inhibit this pathway.

The unmet need is also clear. Amplia says about one in five ovarian cancer patients do not respond adequately to initial chemotherapy, which can limit their ability to proceed to surgery and worsen outcomes. PRROSE will look first at safety, but it will also explore whether adding narmafotinib can increase the proportion of patients who become eligible for successful surgical resection. That gives the trial a practical clinical question: can the drug help turn a poor pre-surgery responder into a better surgical candidate?

The credibility kicker: ANZGOG

For investors, the ANZGOG tie-up matters. This is not Amplia simply adding another line to a slide deck. ANZGOG is the peak gynaecological cancer research organisation across Australia and New Zealand, with a broad clinical trials network spanning major hospitals. The study is investigator initiated, led by Dr Gwo Yaw Ho of Monash Health and Monash University, and sponsored and coordinated by ANZGOG.

Chief executive Dr Chris Burns framed the study as a deliberate broadening of the FAK inhibitor program. “Patients with ovarian cancer who do not respond to initial chemotherapy have very limited treatment options and this study will provide an opportunity to assess whether narmafotinib can improve outcomes for these patients,” he said.

Dr Ho added that the trial reflects ANZGOG’s ability to bring together clinical investigators in areas of high unmet need, with the study designed to generate meaningful evidence for future treatment options.

Pancreatic data remains the main valuation anchor

The ovarian study is useful, but the market will still be taking most of its cues from pancreatic cancer. Amplia’s ACCENT trial has been testing narmafotinib with gemcitabine and Abraxane in first-line advanced pancreatic cancer. The company’s latest ovarian cancer release cites a 31% response rate and interim progression-free survival of 7.6 months for ACCENT, while subsequent market reports on the March mature ACCENT data referred to a centrally reviewed objective response rate of 35.9% and median overall survival of 11.1 months.

That broader context is important because narmafotinib’s investment case is no longer just “interesting science”. It now has human efficacy signals, albeit from studies that still need the harder proof demanded by larger, controlled trials.

The wrinkle: AMPLICITY reminded everyone biotech is not knitting

Investors should also keep the April AMPLICITY halt in mind. Amplia stopped recruitment in that pancreatic cancer trial after three dose-limiting toxicities linked to the FOLFIRINOX chemotherapy regimen, while stating no toxicity concerns had been identified with narmafotinib. The episode does not torpedo the drug, but it does underline the everyday reality of oncology drug development: combinations can be as tricky as the compound itself.

That makes PRROSE interesting because it pairs narmafotinib with a different standard chemotherapy backbone in a different fibrotic cancer setting. Success would not just add an ovarian cancer opportunity; it would also support the broader contention that FAK inhibition can travel across tumour types.

The investor read-through

PRROSE is early, small and exploratory. It will not deliver registration-grade evidence, and investors should not dress it up as such. But it does three useful things for Amplia.

It broadens narmafotinib beyond pancreatic cancer, brings a respected oncology trials group into the tent, and collects tissue and blood biomarker data that could sharpen future patient selection. In biotech land, where the distance between “promising” and “proven” can be measured in years and millions of dollars, that is a sensible next move.

The share price will still dance to pancreatic data, trial design, funding runway and regulatory progress. But with ovarian cancer now formally in the clinic queue, Amplia has added another string to the narmafotinib bow - and this one has a clear biological rationale rather than a mere whiff of opportunism.